Literature DB >> 7309279

Plasma prolactin levels and breast cancer: relation to parity, weight and height, and age at first birth.

H G Kwa, F Cleton, R D Bulbrook, D Y Wang, J L Hayward.   

Abstract

Plasma prolactin has been measured in over 3,500 women volunteers from a normal population. In premenopausal women there was a significant decrease in prolactin levels with increasing parity. However, this effect was transitory since plasma prolactin concentration rose with increasing time after the birth of the last child. There were no significant differences in prolactin levels with respect to height and weight, although overweight compared to underweight women had approximately 15% more plasma prolactin. If prolactin is a carcinogen, then these results are in keeping with the epidemiological findings that multiparity affords protection and that age at last delivery is a risk factor in the development of breast cancer.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7309279     DOI: 10.1002/ijc.2910280106

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  11 in total

Review 1.  Growth hormone and insulin-like growth factor-I in the transition from normal mammary development to preneoplastic mammary lesions.

Authors:  David L Kleinberg; Teresa L Wood; Priscilla A Furth; Adrian V Lee
Journal:  Endocr Rev       Date:  2008-12-15       Impact factor: 19.871

2.  Reproductive factors and colon cancer: the influences of age, tumor site, and family history on risk (Utah, United States).

Authors:  M L Slattery; G P Mineau; R A Kerber
Journal:  Cancer Causes Control       Date:  1995-07       Impact factor: 2.506

3.  Energy balance, early life body size, and plasma prolactin levels in postmenopausal women.

Authors:  Xuefen Su; Susan E Hankinson; Charles V Clevenger; A Heather Eliassen; Shelley S Tworoger
Journal:  Cancer Causes Control       Date:  2008-10-14       Impact factor: 2.506

4.  Decreasing hormonal promotion is key to breast cancer prevention.

Authors:  Lakshmanaswamy Rajkumar; Amy Canada; David Esparza; Katherine Collins; Enrique Moreno; Huyen Duong
Journal:  Endocrine       Date:  2009-02-12       Impact factor: 3.633

5.  Prolactin serum levels and breast cancer: relationships with risk factors and tumour characteristics among pre- and postmenopausal women in a population-based case-control study from Poland.

Authors:  J M Faupel-Badger; M E Sherman; M Garcia-Closas; M M Gaudet; R T Falk; A Andaya; R M Pfeiffer; X R Yang; J Lissowska; L A Brinton; B Peplonska; B K Vonderhaar; J D Figueroa
Journal:  Br J Cancer       Date:  2010-08-24       Impact factor: 7.640

6.  Evidence that an early pregnancy causes a persistent decrease in the number of functional mammary epithelial stem cells--implications for pregnancy-induced protection against breast cancer.

Authors:  Stefan K Siwko; Jie Dong; Michael T Lewis; Hao Liu; Susan G Hilsenbeck; Yi Li
Journal:  Stem Cells       Date:  2008-09-11       Impact factor: 6.277

7.  Bioactive prolactin levels and risk of breast cancer: a nested case-control study.

Authors:  Shelley S Tworoger; Megan S Rice; Bernard A Rosner; Yvonne B Feeney; Charles V Clevenger; Susan E Hankinson
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-10-14       Impact factor: 4.254

8.  Circulating prolactin levels and risk of epithelial ovarian cancer.

Authors:  Tess V Clendenen; Alan A Arslan; Anna E Lokshin; Mengling Liu; Eva Lundin; Karen L Koenig; Franco Berrino; Goran Hallmans; Annika Idahl; Vittorio Krogh; Annekatrin Lukanova; Adele Marrangoni; Paola Muti; Brian M Nolen; Nina Ohlson; Roy E Shore; Sabina Sieri; Anne Zeleniuch-Jacquotte
Journal:  Cancer Causes Control       Date:  2013-02-03       Impact factor: 2.506

Review 9.  Prolactin and breast cancer etiology: an epidemiologic perspective.

Authors:  Shelley S Tworoger; Susan E Hankinson
Journal:  J Mammary Gland Biol Neoplasia       Date:  2008-02-02       Impact factor: 2.673

10.  Insulin-like growth factor (IGF)-I obliterates the pregnancy-associated protection against mammary carcinogenesis in rats: evidence that IGF-I enhances cancer progression through estrogen receptor-alpha activation via the mitogen-activated protein kinase pathway.

Authors:  Gudmundur Thordarson; Nicole Slusher; Harriet Leong; Dafne Ochoa; Lakshmanaswamy Rajkumar; Raphael Guzman; Satyabrata Nandi; Frank Talamantes
Journal:  Breast Cancer Res       Date:  2004-06-04       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.